Melrose Industries PLC issues the following Interim Management Statement for the Period from 1 July 2014 to today (the "Period").
EXECUTIVE SUMMARY
Trading is in line with expectations. This has been a busy period for transactions.
On 31 October 2014 Elster Gas acquired Eclipse, Inc. ("Eclipse"), a US based specialist in the complementary field of low-temperature combustion technology, for £99 million, creating an opportunity to strengthen the Elster Gas business and enhance shareholder value.
On 12 November 2014 the sale of Bridon was completed for an enterprise value of £365 million, meaning the original equity investment by Melrose more than doubled.
Together these transactions are illustrations of the successful and continuing implementation of our "buy, improve and sell" business model.
ELSTER
Elster Gas revenue is up 4% in the Period compared to the same period last year, matched by a very similar rise in order intake. This rate of growth is consistent with the longer term trends expected in its markets and the strategy to improve the profit margin achieved on these sales continues to meet expectations.
Elster Electricity is a business with very high seasonality towards the last quarter of the calendar year. It is pleasing to note that sales are up 5% in the Period compared to the same period last year and order activity is consistent with expectations for the year. Management is fully focused on turning orders into sales.
Of the Elster businesses, Elster Water has seen the most significant increase to headline operating margins since acquisition and its second half margins are in line with expectations.
BRUSH
As discussed in previous trading statements Brush continues to experience slower turbogenerator sales offset, in part, by improved aftermarket performance. The longer term future for Brush remains positive as the business is well placed in its stronger end markets. The new China factory, which is due to open towards the end of 2015, remains on time and on budget.
EXCHANGE
Where relevant all numbers and percentages quoted in this Statement are calculated at constant currency. Consistent with the first half of the year an adverse currency effect of approximately 7% is expected for the full year assuming exchange rates remain at levels they have been recently.
CASH GENERATION AND NET DEBT
The underlying cash generation of the Group remains good. After the purchase of Eclipse and the sale of Bridon, leverage at the end of the year is expected to be below 2x EBITDA1.
RETURN OF CAPITAL
Early next year the Board of Melrose expects to recommend a return of capital to shareholders. The exact amount is yet to be decided but it is expected to be approximately £200 million.
OUTLOOK
World economies continue to be difficult to forecast with any degree of certainty. However, Melrose is well placed in its end markets and has further opportunities to improve its businesses to create shareholder value. Continuing tough market conditions would also position Melrose well for the next stage of its development providing the opportunity to create further shareholder value through acquisition.
1 EBITDA - headline earnings before interest, tax, depreciation and amortisation
-ends-
Enquiries:
CTF Corporate & Financial:
Charlotte McMullen +44 (0)7921 881800
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.